Analysts Set GSK plc (LON:GSK) PT at GBX 1,805.83

Shares of GSK plc (LON:GSK) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is GBX 1,805.83 ($23.38).

A number of brokerages recently commented on GSK. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank lowered their price objective on GSK from GBX 1,820 ($23.56) to GBX 1,600 ($20.71) and set a “buy” rating on the stock in a research report on Friday, November 29th.

GSK Trading Down 2.7 %

Shares of LON:GSK opened at GBX 1,517 ($19.64) on Wednesday. The stock’s 50-day simple moving average is GBX 1,415.73 and its two-hundred day simple moving average is GBX 1,444.77. The stock has a market capitalization of £61.56 billion, a price-to-earnings ratio of 24.51, a PEG ratio of 1.24 and a beta of 0.31. GSK has a 52-week low of GBX 1,282.50 ($16.60) and a 52-week high of GBX 1,823.50 ($23.61). The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts expect that GSK will post 175.980975 EPS for the current year.

Insider Activity at GSK

In other GSK news, insider Emma Walmsley sold 120,653 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.81), for a total transaction of £1,753,088.09 ($2,269,663.50). Also, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction dated Friday, December 20th. The stock was purchased at an average cost of GBX 1,315 ($17.02) per share, for a total transaction of £19,725 ($25,537.29). 1.61% of the stock is owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.